Development and validation of hypermethylated gene markers in cervical cytological samples for detecting endometrial cancer (EndoMethy-I trial) - Scorecard - MDSpire
Advertisement
Development and validation of hypermethylated gene markers in cervical cytological samples for detecting endometrial cancer (EndoMethy-I trial)
Clinical Scorecard: Identification and Assessment of Hypermethylated Gene Markers in Cervical Samples for Endometrial Cancer Detection (EndoMethy-I Study)
At a Glance
Category
Detail
Condition
Endometrial Cancer
Key Mechanisms
Hypermethylation of gene promoters as a mechanism for tumor suppressor gene inactivation.
Target Population
Women with suspected endometrial cancer-related symptoms or high-risk factors.
Care Setting
Prospective observational cohort study.
Key Highlights
Eleven genes related to endometrial cancer were evaluated using a methylation array.
In the validation set, sensitivity was 94.6% and specificity was 92.8% for detecting endometrial cancer.
Methylation assays of CDO1, CELF4, and NEFM provide a reliable strategy for detection.
Cervical cytology combined with methylation markers improves diagnostic accuracy.
Current noninvasive screening methods for endometrial cancer remain limited.
Guideline-Based Recommendations
Diagnosis
Use of transvaginal ultrasound (TVS) in conjunction with endometrial biopsy for diagnosis.
Management
Methylation assays for detecting endometrial cancer in cervical cytological samples.
Monitoring & Follow-up
Integration of clinical parameters such as bleeding symptoms and endometrial thickness.
Risks
Invasive procedures like endometrial biopsy are associated with potential complications.
Patient & Prescribing Data
Women presenting with abnormal uterine bleeding or postmenopausal bleeding.
Methylation markers may serve as noninvasive diagnostic tools.
Clinical Best Practices
Consider noninvasive methylation assays as a first-line evaluation method.
Utilize cervical cytology in conjunction with methylation markers for improved detection.
